Abstract
The histone deacetylase inhibitors (HDIs) are a new class of antineoplastic agents currently being evaluated in clinical trials. While these agents have been studied extensively in the laboratory, only recently has their mechanism of action begun to be elucidated. Several structural classes of compounds have been shown to exert histone deacetylase inhibition, including sodium n-butyrate, suberoylanilide hydroxamic acid, LAQ824, CI-994, MS-275, and depsipeptide. The HDIs have been shown to induce differentiation, to decrease cell proliferation, and to induce cell death. HDIs are thought to exert their anti-neoplastic effects by altering the expression of genes that play a role in the control of cell growth, and transformation. The HDIs have specific and well-defined effects on cancer cells. Preliminary results from clinical trials suggest that these agents are very promising. While there were sporadic case reports of activity using the early generation HDIs, dramatic responses have recently been observed in patients with T-cell lymphomas treated with depsipeptide, one of the newer agents. With the well-defined molecular effects on cancer cells, surrogate markers can be analyzed for evidence of activity and efficacy using either tumor samples or normal tissue. Presented in this review are details from clinical trials with both earlier and newer generations of HDIs. Toxicities specific to this class of agents are outlined and possibilities for rational combination therapies are discussed.
Keywords: Histone deacetylase inhibitors.
Current Pharmaceutical Design
Title: A Review of Depsipeptide and Other Histone Deacetylase Inhibitors in Clinical Trials
Volume: 10 Issue: 19
Author(s): Richard Piekarz and Susan Bates
Affiliation:
Keywords: Histone deacetylase inhibitors.
Abstract: The histone deacetylase inhibitors (HDIs) are a new class of antineoplastic agents currently being evaluated in clinical trials. While these agents have been studied extensively in the laboratory, only recently has their mechanism of action begun to be elucidated. Several structural classes of compounds have been shown to exert histone deacetylase inhibition, including sodium n-butyrate, suberoylanilide hydroxamic acid, LAQ824, CI-994, MS-275, and depsipeptide. The HDIs have been shown to induce differentiation, to decrease cell proliferation, and to induce cell death. HDIs are thought to exert their anti-neoplastic effects by altering the expression of genes that play a role in the control of cell growth, and transformation. The HDIs have specific and well-defined effects on cancer cells. Preliminary results from clinical trials suggest that these agents are very promising. While there were sporadic case reports of activity using the early generation HDIs, dramatic responses have recently been observed in patients with T-cell lymphomas treated with depsipeptide, one of the newer agents. With the well-defined molecular effects on cancer cells, surrogate markers can be analyzed for evidence of activity and efficacy using either tumor samples or normal tissue. Presented in this review are details from clinical trials with both earlier and newer generations of HDIs. Toxicities specific to this class of agents are outlined and possibilities for rational combination therapies are discussed.
Export Options
About this article
Cite this article as:
Piekarz Richard and Bates Susan, A Review of Depsipeptide and Other Histone Deacetylase Inhibitors in Clinical Trials, Current Pharmaceutical Design 2004; 10 (19) . https://dx.doi.org/10.2174/1381612043383980
DOI https://dx.doi.org/10.2174/1381612043383980 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Archaeosome Immunostimulatory Vaccine Delivery System
Current Drug Delivery Inflammation and Cancer: When NF-κB Amalgamates the Perilous Partnership
Current Cancer Drug Targets Targeting Protein Degradation in Cancer Treatment
Current Chemical Biology Editorial (Hot Topic:Recent Advance in the Studies of Beta-glucans for Cancer Therapy)
Anti-Cancer Agents in Medicinal Chemistry Anti-TNF and Crohns Disease: When Should we Start?
Current Drug Targets Targeting Glioblastoma: The Current State of Different Therapeutic Approaches
Current Neuropharmacology Targeting Signaling Pathways in Multiple Myeloma
Current Pharmaceutical Biotechnology Trends in Utilization of the Pharmacological Potential of Chalcones
Current Clinical Pharmacology Metformin for Prevention and Treatment of Colon Cancer: A Reappraisal of Experimental and Clinical Data
Current Drug Targets Traditional Chinese Medicine Remedy to Jury: The Pharmacological Basis for the Use of Shikonin as an Anticancer Therapy
Current Medicinal Chemistry Angiotensin Peptides and Lung Cancer
Current Cancer Drug Targets Anticancer Agents: Towards the Future
Current Medicinal Chemistry - Anti-Cancer Agents Irinotecan for Treatment of Childhood Cancers: A Promising Therapeutic Partner
Current Cancer Therapy Reviews Preventing and Treating Anthracycline-Related Cardiotoxicity in Survivors of Childhood Cancer
Current Cancer Therapy Reviews Targeted Multifunctional Lipid-Based Nanocarriers for Image-Guided Drug Delivery
Anti-Cancer Agents in Medicinal Chemistry Novel Agents Targeting Bioactive Sphingolipids for the Treatment of Cancer
Current Medicinal Chemistry Targeting the BH3 Domain of Bcl-2 Family Proteins. A Brief History From Natural Products to Foldamers As Promising Cancer Therapeutic Avenues
Current Medicinal Chemistry Thalidomide in Multiple Myeloma
Current Pharmaceutical Biotechnology Immunohistochemical and Serological 90K / Mac-2BP Detection in Hepatocellular Carcinoma Patients: Different Behaviour of Two Monoclonal Antibodies
Medicinal Chemistry Editorial Review of 2014
Current Radiopharmaceuticals